Literature DB >> 18198072

[Visceral leishmaniasis and HIV infection in the HAART era].

Nuno Marques1, S Cabral, R Sá, F Coelho, J Oliveira, J G Saraiva da Cunha, A Meliço Silvestre.   

Abstract

Visceral Leishmaniasis is an endemic infection in Portugal, as well as in other Mediterranean basin countries, where it has become a frequent complication of HIV infection. There are several studies published about Leishmania/HIV co-infection, however some particularities of its epidemiology, pathogenesis and especially of its treatment and prophylaxis remain unclear and undefined. The authors review some aspects of this co-infection, particularly epidemiology, clinical classic manifestations and laboratory features, diagnosis, treatment, prophylaxis and prevention and report the casuistic of the Infectious Diseases Department of the University Hospital of Coimbra during the last ten years (1996-2006) in the HAART (<<highly active antiretroviral therapy>>) era. Visceral Leishmaniasis behaves as an opportunistic infection in HIV-infected patients and should be considered as an AIDS-defining disease. Nowadays and according to World Health Organization, VL is the second most important protozoan disease and one of the most neglected; therefore the establishment of treatment and prophylaxis guidelines is urgent.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18198072

Source DB:  PubMed          Journal:  Acta Med Port        ISSN: 0870-399X


  6 in total

1.  Proteomic analysis reveals differentially abundant proteins probably involved in the virulence of amastigote and promastigote forms of Leishmania infantum.

Authors:  Luiz Fialho Junior; Simone da Fonseca Pires; Richard Burchmore; Suzanne McGill; Stefan Weidt; Jeronimo Conceição Ruiz; Frederico Goncalves Guimarães; Alexander Chapeourouge; Jonas Perales; Hélida Monteiro de Andrade
Journal:  Parasitol Res       Date:  2021-01-08       Impact factor: 2.289

2.  Melittin induces in vitro death of Leishmania (Leishmania) infantum by triggering the cellular innate immune response.

Authors:  Andreia Vieira Pereira; Gustavo de Barros; Erika Gracielle Pinto; Andre Gustavo Tempone; Ricardo de Oliveira Orsi; Lucilene Delazari Dos Santos; Sueli Calvi; Rui Seabra Ferreira; Daniel Carvalho Pimenta; Benedito Barraviera
Journal:  J Venom Anim Toxins Incl Trop Dis       Date:  2016-01-08

3.  Visceral leishmaniasis and HIV/AIDS in Brazil: Are we aware enough?

Authors:  Marcia Leite de Sousa-Gomes; Gustavo Adolfo Sierra Romero; Guilherme Loureiro Werneck
Journal:  PLoS Negl Trop Dis       Date:  2017-09-25

4.  Does timing of antiretroviral treatment influence treatment outcomes of visceral leishmaniasis in Northwest Ethiopia?

Authors:  Endashaw M Aderie; Ermias Diro; Rony Zachariah; Marcio Silveira da Fonseca; Charles Abongomera; Bethabile L Dolamo; Koert Ritmeijer
Journal:  Trans R Soc Trop Med Hyg       Date:  2017-03-01       Impact factor: 2.184

5.  HIV aspartyl peptidase inhibitors interfere with cellular proliferation, ultrastructure and macrophage infection of Leishmania amazonensis.

Authors:  Lívia O Santos; Fernanda A Marinho; Ellen F Altoé; Bianca S Vitório; Carlos R Alves; Constança Britto; Maria Cristina M Motta; Marta H Branquinha; André L S Santos; Claudia M d'Avila-Levy
Journal:  PLoS One       Date:  2009-03-26       Impact factor: 3.240

6.  Plants with anti-Leishmania activity: Integrative review from 2000 to 2011.

Authors:  Ana Maria G Brito; Derivaldo Dos Santos; Sheyla A Rodrigues; Renan G Brito; Lauro Xavier-Filho
Journal:  Pharmacogn Rev       Date:  2013-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.